DUBLIN — Research and Markets (http://www.researchandmarkets.com/research/h78zrm/pituitary_acth) has announced the addition of the “Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review, H2 2013” report to their offering.
‘Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review, H2 2013’ provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing’s Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing’s Disease).
Scope
– A snapshot of the global therapeutic scenario for Pituitary ACTH Hypersecretion (Cushing’s Disease).
– A review of the Pituitary ACTH Hypersecretion (Cushing’s Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Pituitary ACTH Hypersecretion (Cushing’s Disease) pipeline on the basis of route of administration and molecule type.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.
Reasons to buy
– Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing’s Disease).
– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
– Devise corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing’s Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned
Isis Pharmaceuticals, Inc.
Ipsen S.A.
Novartis AG
Corcept Therapeutics Incorporated
HRA Pharma, SA
Cortendo Invest AB
Orphagen Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/h78zrm/pituitary_acth
About Research and Markets
Research and Markets is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Filed under: Cushing's, Rare Diseases, Treatments | Tagged: ACTH, Adrenocorticotropic hormone, Cortendo Invest AB, Cushing Syndrome, Cushing's Disease, H2 2013, HRA Pharma, Ipsen, Isis Pharmaceuticals, Key, Market, Novartis, Orphagen, pipeline, therapy |
CushieBlog 
Leave a Reply